In a 74-year-old woman with a seizure disorder who is experiencing dizziness on levetiracetam, which antiepileptic drug would be an appropriate alternative?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 2, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Alternative Antiepileptic Drug for Levetiracetam-Induced Dizziness in a 74-Year-Old Woman

Valproate 20-30 mg/kg IV (or oral equivalent) is the preferred alternative to levetiracetam in this elderly patient, offering superior efficacy (88% seizure control) with minimal cardiovascular risk (0% hypotension), though it requires monitoring for hepatotoxicity and sedation. 1

Primary Recommendation: Valproate

Valproate should be the first-line replacement for levetiracetam in this 74-year-old woman experiencing dizziness. 1 The evidence supporting valproate is compelling:

  • Efficacy: Achieves 88% seizure control as a second-line agent, superior to other alternatives 1
  • Safety profile: 0% hypotension risk, particularly important in elderly patients prone to falls from orthostatic changes 1
  • Tolerability: Well-tolerated in elderly populations with appropriate monitoring 1

Dosing Protocol for Valproate

  • Initial dose: 20-30 mg/kg IV over 5-20 minutes for acute situations 1
  • Oral maintenance: Typically 500-1000 mg daily divided into 2-3 doses, titrated based on response 1
  • Monitoring: Liver function tests due to hepatotoxicity risk, particularly in elderly patients 1

Critical Contraindication

Do not use valproate if this patient is of childbearing potential, as it carries significantly increased risks of fetal malformations and neurodevelopmental delay. 1 At age 74, this is unlikely to be a concern unless specific circumstances exist.

Alternative Option: Lamotrigine

If valproate is contraindicated or not tolerated, lamotrigine represents the next best alternative for focal epilepsy in elderly patients. 2

  • Efficacy: Superior to levetiracetam for time to 12-month remission (hazard ratio 1.32,95% CI 1.05-1.66) 2
  • Tolerability: Lower adverse reaction rate (33%) compared to levetiracetam (44%) 2
  • Titration requirement: Slow titration over several weeks is mandatory to minimize risk of serious skin rash 1

Lamotrigine Dosing

Start at 25 mg daily for 2 weeks, then increase by 25-50 mg every 1-2 weeks to a target maintenance dose of 100-200 mg daily divided into two doses. 1

Third-Line Option: Lacosamide

Lacosamide is a reasonable third choice if both valproate and lamotrigine fail or are contraindicated. 1

  • Availability: Both IV and oral formulations available 1
  • Tolerability: Comparable safety profile between routes 1
  • Common adverse effects: Dizziness (which may not resolve the patient's primary complaint), headache, back pain, and somnolence 1

Options to Avoid in This Elderly Patient

Phenytoin/Fosphenytoin

Avoid phenytoin/fosphenytoin as a chronic maintenance agent in this 74-year-old patient:

  • 12% hypotension risk requiring continuous cardiac monitoring 1
  • Significant drug interactions due to cytochrome P450 enzyme induction 1
  • Higher adverse effect burden in elderly patients 1

Carbamazepine

Carbamazepine should not be used as it has no role in acute seizure management and carries significant drug interaction risks. 1

Zonisamide

Zonisamide is inferior to lamotrigine for focal epilepsy:

  • Higher adverse reaction rate (45%) compared to lamotrigine (33%) 2
  • More costly and less effective than lamotrigine (dominated in economic analysis) 2

Clinical Approach to Switching

Step 1: Confirm Levetiracetam as the Cause

  • Verify medication compliance by checking serum levetiracetam levels 1
  • Rule out other causes of dizziness: orthostatic hypotension, vestibular dysfunction, polypharmacy interactions 1
  • Document seizure control on current regimen before switching 1

Step 2: Transition Strategy

For valproate: Can initiate while tapering levetiracetam, as there are no significant pharmacokinetic interactions between these agents. 1

For lamotrigine: Must use slow cross-titration over 6-8 weeks due to rash risk. Start lamotrigine at low dose while maintaining levetiracetam, then gradually taper levetiracetam once lamotrigine reaches therapeutic levels. 1

Step 3: Monitoring During Transition

  • Seizure frequency: Question patient about seizure occurrences at each follow-up 1
  • Adverse effects: Monitor for sedation, ataxia, tremor with valproate; rash with lamotrigine 1
  • Laboratory monitoring: Liver function tests for valproate 1

Special Considerations in Elderly Patients

Age-Related Pharmacokinetic Changes

  • Valproate protein binding is reduced in elderly, increasing free fraction and potentially requiring lower doses 1
  • Renal function decline may affect drug clearance, though valproate is primarily hepatically metabolized 1

Polypharmacy Concerns

Valproate offers a lower risk of drug-drug interactions compared to enzyme-inducing agents like phenytoin or carbamazepine, making it particularly suitable for elderly patients on multiple medications. 1

Common Pitfalls to Avoid

  1. Do not abruptly discontinue levetiracetam without establishing therapeutic levels of the replacement agent, as this risks breakthrough seizures 1

  2. Do not skip serum drug level monitoring when optimizing the new agent, as non-compliance or inadequate dosing are common causes of apparent treatment failure 1

  3. Do not attribute all dizziness to levetiracetam without excluding other reversible causes such as dehydration, orthostatic hypotension, or concurrent medications 1

  4. Do not use combination therapy prematurely—optimize monotherapy with the new agent at maximum tolerated doses before considering polytherapy 1

References

1
Guideline

Status Epilepticus Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What alternative medication might be considered for a 61-year-old male with seizure disorders, currently taking abdominal (abdominal) matrix, likely referring to (Anti-Epileptic Drug), to reduce the risk of serious arrhythmias given his history of Heart Failure with Preserved Ejection Fraction (HFpEF)?
In a 76‑year‑old man taking levetiracetam (Keppra) 500 mg twice daily with a serum concentration of 5.7 µg/mL, is this level therapeutic and what dose adjustment is recommended?
In a 76-year-old male nursing-home resident taking levetiracetam 500 mg twice daily with a serum level of 5.7 µg/mL, should the dose be adjusted?
How should I manage a 26‑year‑old man with epilepsy on Keppra (levetiracetam) 750 mg twice daily who has had four generalized tonic‑clonic seizures, severe rhabdomyolysis, and acute kidney injury with markedly reduced renal function?
What labs should be ordered for a patient transitioning from Keppra (levetiracetam) to Zonisamide while on Lamictal (lamotrigine)?
How should I adjust therapy for my type 2 diabetic patient whose A1c rose from 9.3% to 10.3% while on metformin (Glucophage) 500 mg twice daily, insulin glargine 20 U at bedtime, and a sliding‑scale of rapid‑acting insulin (Novolog) with meals?
How should I manage akathisia in a patient who is taking lurasidone?
What are the components of a modern anesthetic vaporiser and how does it operate to deliver a precise volatile‑agent concentration?
How should I manage a female patient with worsening post‑bariatric hypoglycemia, now experiencing frequent episodes, chest pressure and near‑syncope over the past 1.5 years?
What is the recommended first‑line management for an adult with complex post‑traumatic stress disorder (C‑PTSD)?
Which insulin is most similar to Novolin NPH (neutral protamine Hagedorn insulin)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question